DNA transcription is a tightly choreographed event: How RNA polymerase II regulates the dance

Life's instructions are written in DNA, but it is the enzyme RNA polymerase II (Pol II) that reads the script, transcribing ...
ScienceAlert on MSN

New 'Mutation Hotspot' Discovered in The Human Genome

Scientists have pinpointed precise regions in the human genome where DNA is most likely to develop a mutation.
The Scientist

DNA Polymerase Works in Short Bursts Rather than One Long Stretch

Biology lectures teach students that when a cell’s replication machinery comes together, DNA polymerase takes off down the double-helix like a car on a highway ...
EurekAlert!

Discovery identifies a highly efficient human reverse transcriptase that can write RNA sequences into DNA

Correction 6/18/21: The original version of this article stated that polymerase theta was the first mammalian polymerase with the ability to transcribe RNA into DNA. In fact, other polymerases have ...
The Scientist

Enzymatic DNA Synthesis: Going to Great Lengths

There’s been this dream for decades. What if we could just print out an entire gene directly, one base at a time? —Daniel Lin-Arlow, Ansa Biotechnologies As scientists set their sights on cell and ...

Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, ...
Fierce Biotech

Artios Pharma secures $115M series D to ramp up clinical efforts with DNA damage response pipeline

Artios Pharma collected $115 million from an oversubscribed series D that will support its growing ambitions for its pipeline ...
Morningstar

Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

STATEN ISLAND, N.Y., Oct. 9, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule ...